Potential therapeutic relevance of adenosine A 2B and A 2A receptors in the central nervous system

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 6, 2012, Pages 664-674

  Popoli, Patrizia ^a   Pepponi, Rita ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adenosine A2 receptors; Adenosine A2A receptors; Central Nervous System; Drug target; Neurodegeneration; Neuroprotection

Indexed keywords

2 [4 (2 CARBOXYETHYL) PHENETHYLAMINO] ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2, 3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL) PYRROLO [1, 2, 3 DE] [1, 4] BENZOXAZINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL) PYRAZOLO [4, 3 E] [1, 2, 4] TRIAZOLO [1, 5 C] PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; METHYLXANTHINE; MNI 420; MRS 1706; PLACEBO; PRELADENANT; TOZADENANT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTE; BRAIN ISCHEMIA; DRUG DEPENDENCE; EPILEPSY; HUMAN; MENTAL DISEASE; NERVE FIBER GROWTH; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NOCICEPTION; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SPINAL CORD INJURY; TASTE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; CENTRAL NERVOUS SYSTEM; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B;

EID: 84869017768     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712803581100     Document Type: Review

References (149)

1. Stehle, J.H.; Rivkees, S.A.; Lee, J.J.; Weaver, D.R.; Deeds, J.D.; Reppert, S.M. Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol. Endocrinol., 1992, 6, 384-393.
2. Dixon, A.K.; Gubitz, A.K.; Sirinathsinghji, D.J.; Richardson, P.J.; Freeman, T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol., 1996, 118(6), 1461-1468.
3. Feoktistov, I.; Biaggioni, I. Adenosine A2B receptors. Pharmacol. Rev., 1997, 49, 381-402.
4. Feoktistov, I.; Murray, J.J.; Biaggioni, I. Positive modulation of intracellular Ca2+ levels by adenosine A2b receptors, prostacyclin, and prostaglandin E1 via a cholera toxin-sensitive mechanism in human erythroleukemia cells. Mol. Pharmacol., 1994, 45, 1160-1167.
5. Linden, J.; Thai, T.; Figler, H.; Jin, X.; Robeva, A.S. Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q)in human embryonic kidney 293 cells and HMC-1 mast cells. Mol. Pharmacol., 1999, 56, 705-713.
6. Linden, J.; Auchampach, J.A.; Jin, X.; Figler, R.A. The structure and function of A1 and A2B adenosine receptors. Life Sci., 1998, 62, 1519-1524.
7. Schulte, G.; Fredholm, B.B. Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol. Pharmacol., 2000, 58, 477-482.
8. Feoktistov, I.; Goldstein, A.E.; Biaggioni, I. Role of p38 mitogenactivated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. Mol. Pharmacol., 1999, 55, 726-734.
9. Schulte, G.; Fredholm, B.B. The G(s)-coupled adenosine A(2B) receptor recruits divergent pathways to regulate ERK1/2 and p38. Exp. Cell Res., 2003, 290, 168-176.
10. Feoktistov, I.; Biaggioni, I. Adenosine A2B receptors. Pharmacol. Rev., 1997, 49, 381-402.
11. Kuno, A.; Critz, S.D.; Cui, L.; Solodushko, V.; Yang, X.M.; Krahn, T.; Albrecht, B.; Philipp, S.; Cohen, M.V.; Downey, J.M. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J. Mol. Cell Cardiol., 2007, 43(3), 262-271.
12. Kuno, A.; Walker, S.; Dost, T.; Cohen, M.V.; Downey, J.M. Adenosine A2b receptors unexpectedly activate cardioprotective kinases through Gi rather than Gs. FASEB J., 2009, 23, 1026-1034.
13. Cohen, M.V.; Yang, X.; Downey, J.M. A(2b) adenosine receptors can change their spots. Br. J. Pharmacol., 2010, 159(8), 1595-1597.
14. Latini, S.; Pedata, F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem., 2001, 79(3), 463-484.
15. Haskó, G.; Linden, J.; Cronstein, B.; Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov., 2008, 7(9), 759-770.
16. Feoktistov, I.; Biaggioni, I. Adenosine A2B receptors. Pharmacol. Rev., 1997, 49(4), 381-402.
17. Aherne, C.M.; Kewley, E.M.; Eltzschig, H.K. The resurgence of A2B adenosine receptor signaling. Biochim. Biophys. Acta, 2011, 1808(5), 1329-1339.
18. Koscsó, B.; Csóka, B.; Selmeczy, Z.; Himer, L.; Pacher, P.; Virág, L.; Haskó, G. Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process. J. Immunol., 2012, 188(1), 445-453.
19. Zhang, J.G.; Hepburn, L.; Cruz, G.; Borman, R.A.; Clark, K.L. The role of adenosine A2A and A2B receptors in the regulation of TNF-alpha production by human monocytes. Biochem. Pharmacol., 2005, 69(6), 883-889.
20. Fiebich, B.L.; Biber, K.; Gyufko, K.; Berger, M.; Bauer, J.; van Calker, D. Adenosine A2b receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J. Neurochem., 1996, 66(4), 1426-1431.
21. Rosi, S.; McGann, K.; Hauss-Wegrzyniak, B.; Wenk, G.L. The influence of brain inflammation upon neuronal adenosine A2B receptors. J. Neurochem., 2003, 86(1), 220-227.
22. Trincavelli, M.L.; Marroni, M.; Tuscano, D.; Ceruti, S.; Mazzola, A.; Mitro, N.;, Abbracchio, M.P.; Martini, C. Regulation of A2B adenosine receptor functioning by tumour necrosis factor a in human astroglial cells. J. Neurochem., 2004, 91(5), 1180-1190.
23. Trincavelli, M.L.; Tonazzini, I.; Montali, M.; Abbracchio, M.P.; Martini, C. Short-term TNF-Alpha treatment induced A2B adenosine receptor desensitization in human astroglial cells. J. Cell. Biochem., 2008, 104(1), 150-161.
24. Csóka, B.; Németh, Z.H.; Rosenberger, P.; Eltzschig, H.K.; Spolarics, Z.; Pacher, P.; Selmeczy, Z.; Koscsó, B.; Himer, L.; Vizi, E.S.; Blackburn, M.R.; Deitch, E.A.; Haskó, G. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J. Immunol., 2010, 185(1), 542-550.
25. Yamagata, K.; Hakata, K.; Maeda, A.; Mochizuki, C.; Matsufuji, H.; Chino, M.; Yamori, Y. Adenosine induces expression of glial cell line-derived neurotrophic factor (GDNF) in primary rat astrocytes. Neurosci. Res., 2007, 59(4), 467-474.
26. Porter, J.T.; McCarthy, K.D. Adenosine receptors modulate [Ca2+]i in hippocampal astrocytes in situ. J. Neurochem., 1995, 65, 1515-1523.
27. Pilitsis, J.G.; Kimelberg, H.K. Adenosine receptor mediated stimulation of intracellular calcium in acutely isolated astrocytes. Brain Res., 1998, 798(1-2), 294-303.
28. Jiménez, A.I.; Castro, E.; Mirabet, M.; Franco, R.; Delicato, E.G.; Miras-Portugal, M.T. Potentiation of ATP calcium responses by A2B receptor stimulation and other signals coupled to Gs proteins in type-1 cerebellar astrocytes. Glia, 1999, 26(2), 119-128.
29. Allaman, I.; Lengacher, S.; Magistretti, P.J.; Pellerin, L. A2B receptor activation promotes glycogen synthesis in astrocytes through modulation of gene expression. Am. J. Physiol. Cell. Physiol., 2003, 284(3), 696-704.
30. Bruns, R.F. Role of adenosine in energy supply/demand balance. Nucleosides Nucleotides, 1991, 10, 931-943.
31. Kessey, K.; Trommer, B.L.; Overstreet, L.S.; Ji, T.; Mogul, D.J. A role for adenosine A2 receptors in the induction of long-term potentiation in the CA1 region of rat hippocampus. Brain Res., 1997, 756(1-2), 184-190.
32. Okada, M.; Mizuno, K.; Kaneko, S. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci. Lett., 1996, 212(1), 53-56.
33. Michel, P.P.; Marien, M.; Ruberg, M.; Colpaert, F.; Agid, Y. Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes. J. Neurochem., 1999, 72(5), 2074-2082.
34. Vazquez, J.F.; Clement, H.W.; Sommer, O.; Schulz, E.; van Calker, D. Local stimulation of the adenosine A2B receptors induces an increased release of IL-6 in mouse striatum: an in vivo microdialysis study. J. Neurochem., 2008, 105(3), 904-909.
35. Roseti, C.; Martinello, K.; Fucile, S.; Piccari, V.; Mascia, A.; Di Gennaro, G.; Quarato, P.P.; Manfredi, M.; Esposito, V.; Cantore, G.; Arcella, A.; Limonato, M.; Fredholm, B.B.; Limatola, C.; Miledi, R.; Eusebi, F. Adenosine receptor antagonists alter the stability of human epileptic GABAA receptors. Proc. Natl. Acad. Sci. USA, 2008, 105(39), 15118-15123.
36. Corset, V.; Nguyen-Ba-Charvet, K.T.; Forcet, C.; Moyse, E.; Chédotal, A.; Mehlen, P. Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor. Nature, 2000, 407(6805), 747-750.
37. Stein, E.; Zou, Y.; Poo, M.; Tessier-Lavigne, M. Binding of DCC by netrin-1 to mediate axon guidance independent of adenosine A2B receptor activation. Science, 2001, 291(5510), 1976-1982.
38. Abo-Salem, O.M.; Hayallah, A.M.; Bilkei-Gorzo, A.; Filipek, B.; Zimmer, A.; Müller, C.E. Antinociceptive effects of novel A2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther., 2004, 308(1), 358-366.
39. Dando, R.; Dvoryanchikov, G.; Pereira, E.; Chaudhari, N.; Roper, S.D.; Adenosine enhances sweet taste through A2B receptors in the taste bud. J. Neurosci., 2012, 32(1), 322-330.
40. Kataoka, S.; Baquero, A.; Yang, D.; Shultz, N.; Vandenbeuch, A.; Ravid, K.; Kinnamon, S.C.; Finger T.E. A2BR adenosine receptor modulates sweet taste in circumvallate taste buds. PLoS One, 2012, 7(1), e30032.
41. Jacobson, K.A.; Gao, Z.G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug. Discov., 2006, 5(3), 247-264.
42. Kull, B.; Svenningsson, P.; Fredholm, B.B. Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum. Mol. Pharmacol., 2000, 58(4), 771-777.
43. Schulte, G.; Fredholm, B.B. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal., 2003, 15(9), 813-827.
44. Rosin, D.L.; Robeva, A.; Woodard, R.L.; Guyenet, P.G.; Linden, J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J. Comp. Neurol., 1998, 401(2), 163-186.
45. Moreau, J.L.; Huber, G. Central adenosine A(2A) receptors: an overview. Brain Res. Brain Res. Rev., 1999, 31(1), 65-82.
46. Ferré S.; O'Connor, WT.; Fuxe, K.; Ungerstedt, U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci., 1993, 13(12), 5402-5406.
47. Schiffmann, S.N.; Jacobs, O.; Vanderhaeghen, J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem., 1991, 57(3), 1062-1067.
48. Hettinger, B.D.; Lee, A.; Linden, J.; Rosin, D.L. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol., 2001, 431(3), 331-346.
49. Ciruela, F.; Casadó, V.; Rodrigues, R.J.; Luján, R.; Burgueño, J.; Canals, M.; Borycz, J.; Rebola, N.; Goldberg, S.R.; Mallol, J.; Cortés, A.; Canela, E.I.; López-Giménez, J.F.; Milligan, G.; Lluis, C.; Cunha, R.A.; Ferré, S.; Franco, R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci., 2006, 26(7), 2080-2087.
50. Quiroz, C.; Pearson, V.; Gulyani, S.; Allen, R.; Earley, C.; Ferré, S. Up-regulation of striatal adenosine A(2A) receptors with iron deficiency in rats: effects on locomotion and cortico-striatal neurotransmission. Exp. Neurol., 2010, 224(1), 292-298.
51. Ferré, S.; O'Connor, W.T.; Fuxe, K.; Ungerstedt, U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci., 1993, 13(12), 5402-5406.
52. Ferré, S.; Fredholm, B.B.; Morelli, M.; Popoli, P.; Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci., 1997, 20(10), 482-487.
53. Ferré, S.; Quiroz, C.; Woods, A.S.; Cunha, R.; Popoli, P.; Ciruela, F.; Lluis, C.; Franco, R.; Azdad, K.; Schiffmann, S.N. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr. Pharm. Des., 2008, 14(15), 1468-1474.
54. Tebano, M.T.; Martire, A.; Pepponi, R.; Domenici, M.R.; Popoli, P. Is the functional interaction between adenosine A(2A) receptors and metabotropic glutamate 5 receptors a general mechanism in the brain? Differences and similarities between the striatum and the hippocampus. Purinergic Signal., 2006, 2(4), 619-625.
55. Ferré, S.; Karcz-Kubicha, M.; Hope, B.T.; Popoli, P.; Burgueño, J.; Gutiérrez, M.A.; Casadó, V.; Fuxe, K.; Goldberg, S.R.; Lluis, C.; Franco, R.; Ciruela, F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA, 2002, 99(18), 11940-11945.
56. Carriba, P.; Ortiz, O.; Patkar, K.; Justinova, Z.; Stroik, J.; Themann, A.; Müller, C.; Woods, A.S.; Hope, B.T.; Ciruela, F.; Casadó, V.; Canela, E.I.; Lluis, C.; Goldberg, S.R.; Moratalla, R.; Franco, R.; Ferré, S. Striatal adenosine A2A and cannabinoid CB1receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology, 2007, 32(11), 2249-2259.
57. Coney, A.M.; Marshall, J.M. Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia. J. Physiol., 1998, 509 (Pt 2), 507-518.
58. Popoli, P.; Blum, D.; Martire, A.; Ledent, C.; Ceruti, S.; Abbracchio, M.P. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog. Neurobiol., 2007, 81(5-6), 331-348.
59. Popoli, P.; Blum, D.; Domenici, M.R.; Burnouf, S.; Chern, Y. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Curr. Pharm. Des., 2008, 14(15), 1500-1511.
60. Morelli, M.; Carta, A.R.; Jenner, P. Adenosine A2A receptors and Parkinson's disease. Handb. Exp. Pharmacol., 2009, (193), 589-615.
61. Armentero, M.T.; Pinna, A.; Ferré, S.; Lanciego, J.L.; Müller, C.E.; Franco, R. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther., 2011, 132(3), 280-299.
62. Cristalli, G.; Müller, C.E.; Volpini, R. Recent developments in adenosine A2A receptor ligands. Handb. Exp. Pharmacol., 2009, (193), 59-98.
63. Cassada, D.C.; Tribble, C.G.; Young, J.S.; Gangemi, J.J.; Gohari, A.R.; Butler, P.D.; Rieger, J.M.; Kron, I.L.; Linden, J.; Kern, J.A. Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit. J. Trauma, 2002, 53(2), 225-229.
64. Reece, T.B.; Davis, J.D.; Okonkwo, D.O.; Maxey, T.S.; Ellman, P.I.; Li, X.; Linden, J.; Tribble, C.G.; Kron, I.L.; Kern, J.A. Adenosine A2A analogue reduces long-term neurologic injury after blunt spinal trauma. J. Surg. Res., 2004, 121(1), 130-134.
65. Genovese, T.; Melani, A.; Esposito, E.; Paterniti, I.; Mazzon, E.; Di Paola, R.; Bramanti, P.; Linden, J.; Pedata, F.; Cuzzocrea, S. Selective adenosine A(2a) receptor agonists reduce the apoptosis in an experimental model of spinal cord trauma. J. Biol. Regul. Homeost. Agents, 2010, 24(1), 73-86.
66. Paterniti, I.; Melani, A.; Cipriani, S.; Corti, F.; Mello, T.; Mazzon, E.; Esposito, E.; Bramanti, P.; Cuzzocrea, S.; Pedata, F. Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects. J. Neuroinflammation, 2011, 8, 31-44.
67. Li, Y.; Oskouian, R.J.; Day, Y.J.; Rieger, J.M.; Liu, L.; Kern, J.A.; Linden, J. Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrowderived cells or deletion of the A2A receptor on non-bone marrowderived cells. Neuroscience, 2006, 141(4), 2029-2039.
68. Dai, S.S.; Zhou, Y.G.; Li, W.; An, J.H.; Li, P.; Yang, N.; Chen, X.Y.; Xiong, R.P.; Liu, P.; Zhao, Y.; Shen, H.Y.; Zhu, P.F.; Chen, J.F. Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J. Neurosci., 2010, 30(16), 5802-5810.
69. Gao, Y.; Phillis, J.W. CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci., 1994, 55(3), 61-65.
70. Phillis, J.W. The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res., 1995, 705(1-2), 79-84.
71. Von Lubitz, D.K.; Lin, R.C.; Jacobson, K.A. Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. Eur. J. Pharmacol., 1995, 287(3), 295-302.
72. Bona, E.; Adén, U.; Gilland E.; Fredholm B.B.; Hagberg H. Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology, 1997, 36(9), 1327-1338.
73. Monopoli, A.; Lozza, G.; Forlani, A.; Mattavelli, A.; Ongini, E. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport, 1998, 9(17), 3955-3959.
74. Melani, A.; Pantoni, L.; Bordoni, F.; Gianfriddo, M.; Bianchi, L.; Vannucchi, M.G.; Bertorelli, R.; Monopoli, A.; Pedata, F. The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res., 2003, 959(2), 243-250.
75. Chen, J.F.; Huang, Z.; Ma, J.; Zhu, J.; Moratalla, R.; Standaert, D.; Moskowitz, M.A.; Fink, J.S.; Schwarzschild, M.A. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci., 1999, 19(21), 9192-9200.
76. Bruce-Keller, A.J. Microglial-neuronal interactions in synaptic damage and recovery. J. Neurosci. Res., 1999, 58(1), 191-201.
77. Popoli, P.; Pintor, A.; Domenici, M.R.; Frank, C.; Tebano, M.T.; Pèzzola, A.; Scarchilli, L.; Quarta, D.; Reggio, R.; Malchiodi-Albedi, F.; Falchi, M.; Massotti, M. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci., 2002, 22(5), 1967-1975.
78. Corsi, C.; Melani, A.; Bianchi, L.; Pedata, F. Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport, 2000, 11(11), 2591-2595.
79. Pintor, A.; Quarta, D.; Pezzola, A.; Reggio, R.; Popoli, P. SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum. Eur. J. Pharmacol., 2001, 421(3), 177-180.
80. Pintor, A.; Galluzzo, M.; Grieco, R.; Pèzzola, A.; Reggio, R.; Popoli, P. Adenosine A2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J. Neurochem., 2004, 89(1), 152-156.
81. Matos, M.; Augusto, E.; Dos Santos-Rodriguez, A.; Schwarzschild, M.A.; Chen, J.F.; Cunha, R.A.; Agostinho, P. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia, 2012, 60, 702-716.
82. Melani, A.; Gianfriddo, M.; Vannucchi, M.G.; Cipriani, S.; Baraldi, P.G.; Giovannini, M.G.; Pedata, F. The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res., 2006, 16(1073-1074), 470-480.
83. Melani, A.; Cipriani, S.; Vannucchi, M.G.; Nosi, D.; Donati, C.; Bruni, P.; Giovannini, M.G.; Pedata, F. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain, 2009, 132(Pt 6), 1480-1495.
84. Yu, L.; Huang, Z.; Mariani, J.; Wang, Y.; Moskowitz, M.; Chen, J.F. Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat. Med., 2004, 10(10), 1081-1987.
85. Adén, U.; Halldner, L.; Lagercrantz, H.; Dalmau, I.; Ledent, C.; Fredholm, B.B. Aggravated brain damage after hypoxic ischemia in immature adenosine A2A knockout mice. Stroke, 2003, 34(3), 739-744.
86. Cognato, G.P.; Agostinho, P.M.; Hockemeyer, J.; Müller, C.E.; Souza, D.O.; Cunha, R.A. Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life. J. Neurochem., 2010, 112(2), 453-462.
87. Leite, M.R.; Wilhelm, E.A.; Jesse, C.R.; Brandão, R.; Nogueira, C.W. Protective effect of caffeine and a selective A2A receptor antagonist on impairment of memory and oxidative stress of aged rats. Exp. Gerontol., 2011, (4), 309-315.
88. Dall'Igna, O.P.; Porciúncula, L.O.; Souza, D.O.; Cunha, R.A.; Lara, D.R. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br. J. Pharmacol., 2003, 138(7), 1207-1209.
89. Canas, P.M.; Porciúncula, L.O.; Cunha, G.M.; Silva, C.G.; Machado, N.J.; Oliveira, J.M.; Oliveira, C.R.; Cunha, R.A. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J. Neurosci., 2009, (47), 14741-14751.
90. Arendash, G.W.; Schleif. W.; Rezai-Zadeh, K.; Jackson, E.K.; Zacharia, L.C.; Cracchiolo, J.R.; Shippy, D.; Tan, J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience, 2006, 142(4), 941-952.
91. Arendash, G.W.; Mori, T.; Cao, C.; Mamcarz, M.; Runfeldt, M.; Dickson, A.; Rezai-Zadeh, K.; Tane, J.; Citron, B.A.; Lin, X.; Echeverria, V.; Potter, H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J. Alzheimers Dis., 2009, 17(3), 661-680.
92. Rosso, A.; Mossey, J.; Lippa, C.F. Caffeine: neuroprotective functions in cognition and Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen., 2008, 23(5), 417-422.
93. Maia, L.; de Mendonça, A. Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol., 2002, 9(4), 377-382.
94. Lindsay, J.; Laurin, D.; Verreault, R.; Hébert, R.; Helliwell, B.; Hill, G.B.; McDowell, I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol., 2002, 156(5), 445-453.
95. Eskelinen, M.H.; Kivipelto, M. Caffeine as a protective factor in dementia and Alzheimer's disease. J. Alzheimers Dis., 2010, 20, S167-S174.
96. Santos, C.; Costa, J.; Santos, J.; Vaz-Carneiro, A.; Lunet, N. Caffeine intake and dementia: systematic review and meta-analysis. J. Alzheimers Dis., 2010, 20, S187-S204.
97. Giménez-Llort, L.; Schiffmann, S.N.; Shmidt, T.; Canela, L.; Camón, L.; Wassholm, M.; Canals, M.; Terasmaa, A.; Fernández-Teruel, A.; Tobeña, A.; Popova, E.; Ferré, S.; Agnati, L.; Ciruela, F.; Martínez, E.; Scheel-Kruger, J.; Lluis, C.; Franco, R.; Fuxe, K.; Bader, M. Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiol. Learn. Mem., 2007, 87(1), 42-56.
98. Zhou, S.J.; Zhu, M.E.; Shu, D.; Du, X.P.; Song, X.H.; Wang, X.T.; Zheng, R.Y.; Cai, X.H.; Chen, J.F.; He, J.C. Preferential enhancement of working memory in mice lacking adenosine A(2A)receptors. Brain Res., 2009, 1303, 74-83.
99. Wei C.J.; Singer P.; Coelho J.; Boison D.; Feldon J.; Yee B.K.; Chen J.F. Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learn. Mem., 2011, 18(7), 459-474.
100. Ferré, S.; von Euler, G.; Johansson, B.; Fredholm, B.B.; Fuxe, K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA, 1991, 88(16), 7238-7241.
101. Ferré, S.; Quiroz, C.; Woods, A.S.; Cunha, R.; Popoli, P.; Ciruela, F.; Lluis, C.; Franco, R.; Azdad, K.; Schiffmann, S.N. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr. Pharm. Des., 2008, 14(15), 1468-1474.
102. Ferré, S.; Ciruela, F.; Quiroz, C.; Luján, R.; Popoli, P.; Cunha, R.A.; Agnati, L.F.; Fuxe, K.; Woods, A.S.; Lluis, C.; Franco, R. Adenosine receptor heteromers and their integrative role in striatal function. Sci. World J., 2007, 7, 74-85.
103. Ferré, S.; Fredholm, B.B.; Morelli, M.; Popoli, P.; Fuxe, K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci., 1997, 20(10), 482-487.
104. Steinberg, M.; Shao, H.; Zandi, P.; Lyketsos, C.G.; Welsh-Bohmer, K.A.; Norton, M.C.; Breitner, J.C.; Steffens, D.C.; Tschanz, J.T.; Cache County Investigators. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int. J. Geriatr. Psychiatry, 2008, 23(2), 170-177.
105. Deckert, J. The adenosine A(2A) receptor knockout mouse: a model for anxiety? Int. J. Neuropsychopharmacol., 1998, 1(2), 187-190.
106. Alsene, K.; Deckert, J.; Sand, P.; de Wit, H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology, 2003, 28(9), 1694-1702.
107. Freitag, C.M.; Agelopoulos, K.; Huy, E.; Rothermundt, M.; Krakowitzky, P.; Meyer, J.; Deckert, J.; von Gontard, A.; Hohoff, C. Adenosine A(2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder. Eur. Child. Adolesc. Psychiatry, 2010, (1), 67-74.
108. Deckert, J.; Nöthen, M.M.; Franke, P.; Delmo, C.; Fritze, J.; Knapp, M.; Maier, W.; Beckmann, H.; Propping, P. Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol. Psychiatry, 1998, (1), 81-85.
109. Hamilton, S.P.; Slager, S.L.; De Leon, A.B.; Heiman, G.A.; Klein, D.F.; Hodge, S.E.; Weissman, M.M.; Fyer, A.J.; Knowles, J.A. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology, 2004, 29(3), 558-565.
110. Lam, P.; Hong, C.J.; Tsai, S.J. Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci. Lett., 2005, 378(2), 98-101.
111. Cunha, R.A.; Ferré, S.; Vaugeois, J.M.; Chen, J.F. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr. Pharm. Des., 2008, 14(15), 1512-1524.
112. Ferré, S.; Ciruela, F.; Canals, M.; Marcellino, D.; Burgueno, J.; Casadó, V.; Hillion, J.; Torvinen, M.; Fanelli, F.; Benedetti, Pd.P.; Goldberg, S.R.; Bouvier, M.; Fuxe, K.; Agnati, L.F.; Lluis, C.; Franco, R.; Woods, A. Adenosine A2A-dopamine D2 receptorreceptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord., 2004, 10(5), 265-271.
113. Fuxe, K.; Ferré, S.; Canals, M.; Torvinen, M.; Terasmaa, A.; Marcellino, D.; Goldberg, S.R.; Staines, W.; Jacobsen, K.X.; Lluis, C.; Woods, A.S.; Agnati, L.F.; Franco, R. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J. Mol. Neurosci., 2005, 26(2-3), 209-220.
114. Wardas, J. Potential role of adenosine A2A receptors in the treatment of schizophrenia. Front. Biosci., 2008, 13, 4071-4096.
115. Heffner, T.G.; Wiley, J.N.; Williams, A.E.; Bruns, R.F.; Coughenour, L.L.; Downs, D.A. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology (Berl.), 1989, 98(1), 31-37.
116. Kafka, S.H.; Corbett, R. Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur. J. Pharmacol., 1996, 295(2-3), 147-154.
117. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl.), 1997, 133(2), 107-120.
118. Lucas, P.B.; Pickar, D.; Kelsoe, J.; Rapaport, M.; Pato, C.; Hommer, D. Effects of the acute administration of caffeine in patients with schizophrenia. Biol. Psychiatry, 1990, 28(1), 35-40.
119. Zaslove, M.O.; Russell, R.L.; Ross, E. Effect of caffeine intake on psychotic in-patients. Br. J. Psychiatry, 1991, 159, 565-567.
120. Akhondzadeh, S.; Shasavand, E.; Jamilian, H.; Shabestari, O.; Kamalipour, A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J. Clin. Pharm. Ther., 2000, 25(2), 131-137.
121. Lara, D.R.; Dall'Igna, O.P.; Ghisolfi, E.S.; Brunstein, M.G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(4), 617-629.
122. Kurumaji, A.; Toru, M. An increase in [3H] CGS 21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Res., 1998, 808(2), 320-323.
123. Deckert, J.; Brenner, M.; Durany, N.; Zöchling, R.; Paulus, W.; Ransmayr, G.; Tatschner, T.; Danielczyk, W.; Jellinger, K.; Riederer, P. Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport, 2003, 14(3), 313-316.
124. Urigüen, L.; García-Fuster, M.J.; Callado, L.F.; Morentin, B.; La Harpe, R.; Casadó, V.; Lluis, C.; Franco, R.; García-Sevilla, J.A.; Meana, J.J. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl.), 2009, 206(2), 313-324.
125. Morrison, P.D.; Murray, R.M. From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr. Bull., 2009, 35(4), 668-674.
126. Lodge, D.J.; Grace, A.A. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J. Neurosci., 2007, 27(42), 11424-11430.
127. Cleveland, D.W.; Rothstein, J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci., 2001, 2, 806-819.
128. Van Den Bosch, L.; Van Damme, P.; Bogaert, E.; Robberecht, W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta, 2006, 1762, 1068-1082.
129. Danbolt, N.C. Glutamate uptake. Prog. Neurobiol., 2001, 65, 1-105.
130. Sendtner, M.; Holtmann, B.; Kolbeck, R.; Thoenen, H.; Barde, Y.A. Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature, 1992, 360(6406), 757-759.
131. Lambrechts, D.; Poesen, K.; Fernández-Santiago, R.; Al-Chalabi, A.; Del Bo, R.; Van Vught, P.W.; Khan, S.; Marklund, S.L.; Brockington, A.; van Marion, I.; Anneser, J.; Shaw, C.; Ludolph, A.C.; Leigh, N.P.; Comi, G.P.; Gasser, T.; Shaw, P.J.; Morrison, K.E.; Andersen, P.M.; Van den Berg, L.H.; Thijs, V.; Siddique, T.; Robberecht, W.; Carmeliet, P. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the-2578AA genotype. J. Med. Genet., 2009, 46(12), 840-846.
132. Mojsilovic-Petrovic, J.; Jeong, G.B.; Crocker, A.; Arneja, A.; David, S.; Russell, D.S.; Kalb, R.G. Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J. Neurosci., 2006, 26(36), 9250-63.
133. Beghi, E.; Pupillo, E.; Messina, P.; Giussani, G.; Chiò, A.; Zoccolella, S.; Moglia, C.; Corbo, M.; Logroscino, G.; EURALS Group. Coffee and amyotrophic lateral sclerosis: a possible preventive role. Am. J. Epidemiol., 2011, 174(9), 1002-1008.
134. Wiese, S.; Jablonka, S.; Holtmann, B.; Orel, N.; Rajagopal, R.; Chao, M.V.; Sendtner, M. Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc. Natl. Acad. Sci. USA, 2007, 104(43), 17210-17215.
135. Golder, F.J.; Ranganathan, L.; Satriotomo, I.; Hoffman, M. Lovett-Barr, M.R.; Watters, J.J.; Baker-Herman, T.L.; Mitchell, G.S. Spinal adenosine A2a receptor activation elicits long-lasting phrenic motor facilitation. J. Neurosci., 2008, 28(9), 2033-2042.
136. Ramanathan, M.; Pinhal-Enfield, G.; Hao, I.; Leibovich, S.J. Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol. Biol. Cell, 2007, 18(1), 14-23.
137. Liu, X.L.; Zhou, R.; Pan, Q.Q.; Jia, X.L.; Gao, W.N.; Wu, J.; Lin, J.; Chen, J.F. Geneticin activation of the adenosine A2A receptor attenuates pathologic but not developmental angiogenesis in the mouse retina. Invest. Ophthalmol. Vis. Sci., 2010, 51(12), 6625-6632.
138. Sebastião, A.M.; Ribeiro, J.A. Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection. Br. J. Pharmacol., 2009, 158(1), 15-22.
139. Tebano, M.T.; Martire, A.; Potenza, R.L.; Grò, C.; Pepponi, R.; Armida, M.; Domenici, M.R.; Schwarzschild, M.A.; Chen, J.F.; Popoli, P. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J. Neurochem., 2008, 104(1), 279-286.
140. Sebastião, A.M.; Macedo, M.P.; Ribeiro, J.A. Tonic activation of A(2A) adenosine receptors unmasks, and of A(1) receptors prevents, a facilitatory action of calcitonin gene-related peptide in the rat hippocampus. Br. J. Pharmacol., 2000, 129(2), 374-380.
141. Ribeiro, J.A.; Sebastião, A.M.; de Mendonça, A. Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol., 2002, 68(6), 377-392.
142. Ferré, S.; Lluís, C.; Justinova, Z.; Quiroz, C.; Orru, M.; Navarro, G.; Canela, E.I.; Franco, R.; Goldberg, S.R. Adenosinecannabinoid receptor interactions. Implications for striatal function. Br. J. Pharmacol., 2010, 160(3), 443-453.
143. Tebano, M.T.; Martire, A.; Chiodi, V.; Pepponi, R.; Ferrante, A.; Domenici, M.R.; Frank, C.; Chen, J.F.; Ledent, C.; Popoli, P. Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. J. Neurochem., 2009, 110(6), 1921-1930.
144. Martire, A.; Tebano, M.T.; Chiodi, V.; Ferreira, S.G.; Cunha, R.A.; Köfalvi, A.; Popoli, P. Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. J. Neurochem., 2011, 116(2), 273-280.
145. Giménez-Llort, L.; Schiffmann, S.N.; Shmidt, T.; Canela, L.; Camón, L.; Wassholm, M.; Canals, M.; Terasmaa, A.; Fernández-Teruel, A.; Tobeña, A.; Popova, E.; Ferré, S.; Agnati, L.; Ciruela, F.; Martínez, E.; Scheel-Kruger, J.; Lluis, C.; Franco, R.; Fuxe, K.; Bader, M. Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiol. Learn. Mem., 2007, 87(1), 42-56.
146. Justinová, Z.; Ferré, S.; Redhi, G.H.; Mascia, P.; Stroik, J.; Quarta, D.; Yasar, S.; Müller, C.E.; Franco, R.; Goldberg, S.R. Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. Addict. Biol., 2011, 16(3), 405-415.
147. Filip, M.; Frankowska, M.; Zaniewska, M.; Przegaliski, E.; Muller, C.E.; Agnati, L.; Franco, R.; Roberts, D.C.; Fuxe, K. Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. Brain Res., 2006, 1077(1), 67-80.
148. Shen, H.Y.; Coelho, J.E.; Ohtsuka, N.; Canas, P.M.; Day, Y.J.; Huang, Q.Y.; Rebola, N.; Yu, L.; Boison, D.; Cunha, R.A.; Linden, J.; Tsien, J.Z.; Chen, J.F. A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J. Neurosci., 2008, 28(12), 2970-2975.
149. Orrú, M.; Quiroz, C.; Guitart, X.; Ferré, S. Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum. Neuropharmacology, 2011, 61(5-6), 967-974.